Inotiv, Inc. (NOTV)
NOTV Stock Price Chart
Explore Inotiv, Inc. interactive price chart. Choose custom timeframes to analyze NOTV price movements and trends.
NOTV Company Profile
Discover essential business fundamentals and corporate details for Inotiv, Inc. (NOTV) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
25 Nov 1997
Employees
1.98K
Website
https://www.inotivco.comCEO
Robert W. Leasure Jr.
Description
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
NOTV Financial Timeline
Browse a chronological timeline of Inotiv, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 3 Feb 2026
Upcoming earnings on 2 Dec 2025
EPS estimate is -$0.08.
Earnings released on 6 Aug 2025
EPS came in at -$0.12 surpassing the estimated -$0.15 by +20.00%, while revenue for the quarter reached $130.68M , missing expectations by -2.00%.
Earnings released on 7 May 2025
EPS came in at -$0.18 surpassing the estimated -$0.24 by +25.00%, while revenue for the quarter reached $124.32M , beating expectations by +0.29%.
Earnings released on 5 Feb 2025
EPS came in at -$0.42 matching the estimated -$0.42, while revenue for the quarter reached $119.88M , missing expectations by -4.20%.
Earnings released on 3 Dec 2024
EPS came in at -$0.16 surpassing the estimated -$0.91 by +82.42%, while revenue for the quarter reached $130.42M , beating expectations by +11.53%.
Earnings released on 8 Aug 2024
EPS came in at -$0.20 falling short of the estimated -$0.09 by -122.22%, while revenue for the quarter reached $105.79M , missing expectations by -9.54%.
Earnings released on 15 May 2024
EPS came in at -$0.29 falling short of the estimated $0.05 by -680.00%, while revenue for the quarter reached $119.04M , missing expectations by -8.28%.
Earnings released on 7 Feb 2024
EPS came in at -$0.60 falling short of the estimated $0.07 by -957.14%, while revenue for the quarter reached $135.50M , missing expectations by -1.51%.
Earnings released on 11 Dec 2023
EPS came in at -$0.29 falling short of the estimated $0.11 by -363.64%, while revenue for the quarter reached $140.74M , beating expectations by +0.94%.
Earnings released on 10 Aug 2023
EPS came in at $0.07 surpassing the estimated -$0.10 by +170.00%, while revenue for the quarter reached $157.47M , beating expectations by +12.94%.
Earnings released on 11 May 2023
EPS came in at -$0.34 falling short of the estimated -$0.16 by -112.50%, while revenue for the quarter reached $151.46M , beating expectations by +24.96%.
Earnings released on 10 Jan 2023
EPS came in at -$0.09 surpassing the estimated -$0.37 by +75.68%, while revenue for the quarter reached $122.75M , beating expectations by +3.37%.
Earnings released on 12 Dec 2022
EPS came in at -$9.54 falling short of the estimated -$0.37 by -2.48K%, while revenue for the quarter reached $150.47M .
Earnings released on 10 Aug 2022
EPS came in at -$0.15 falling short of the estimated -$0.04 by -300.00%, while revenue for the quarter reached $172.67M , beating expectations by +21.81%.
Earnings released on 12 May 2022
EPS came in at -$0.24 surpassing the estimated -$0.27 by +11.11%, while revenue for the quarter reached $140.31M , beating expectations by +16.39%.
Earnings released on 10 Feb 2022
EPS came in at -$0.54 falling short of the estimated $0.16 by -437.50%, while revenue for the quarter reached $84.21M , beating expectations by +15.70%.
Earnings released on 16 Dec 2021
EPS came in at -$0.34 falling short of the estimated -$0.14 by -142.86%, while revenue for the quarter reached $30.08M , missing expectations by -59.46%.
Earnings released on 11 Aug 2021
EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached $22.89M , beating expectations by +8.49%.
Earnings released on 5 May 2021
EPS came in at -$0.06 matching the estimated -$0.06, while revenue for the quarter reached $18.75M , beating expectations by +12.89%.
Earnings released on 9 Feb 2021
EPS came in at -$0.03 surpassing the estimated -$0.19 by +84.21%, while revenue for the quarter reached $17.89M , missing expectations by -73.27%.
Earnings released on 21 Dec 2020
EPS came in at -$0.16 , while revenue for the quarter reached $15.77M .
NOTV Stock Performance
Access detailed NOTV performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.